The development of therapeutic antibodies requires optimal formulations for long-term antibody stability. For this, buffer screening approaches are routinely used, in which the thermal stability of a given antibody in different buffers are tested. The buffers typically vary regarding buffer substances, pH values, salt concentrations and other excipients.
The prerequisite for such screening approaches are high measurement precision, low sample consumption, and high throughput. Moreover, it is highly desirable to measure under native conditions, without dilution of the antibody or the requirement to use reporter dyes or other modifications.
Here we present nanoDSF, a label-free, native DSF technique, as the method of choice to perform rapid and precise buffer screening projects for therapeutic antibodies during the drug development process.
